-

BioAge to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021

RICHMOND, Calif.--(BUSINESS WIRE)--BioAge Labs, Inc., is scheduled to present virtually at the 39th Annual J.P. Morgan Healthcare Conference (JPM) on Tuesday, January 12, 2021 at 2:00pm ET. The BioAge leadership team also will be available for one-on-one meetings via BIO Partnering @ JPM from January 11-15, 2021.

Kristen Fortney, BioAge’s chief executive officer, will provide an overview of BioAge’s systems biology and data-driven platform to map the key pathways that drive human aging, pipeline of medicines that target these pathways to reverse or eradicate diseases and extend healthspan, and plans for advancing the company’s first two platform-derived therapies into Phase 2 clinical trials in the first half of 2021.

A live audio webcast along with accompanying slides will be made available in the News section of the company’s website at https://bioagelabs.com/#news.

About BioAge

BioAge is a clinical-stage biotechnology company that develops drugs to treat aging and aging-related diseases. We’ve built a systems biology platform to map out the key molecular pathways that impact healthy human aging, based on proprietary human aging cohorts that have blood samples collected up to 45 years ago with participant -omics data that is tied to detailed medical follow-up records over their lifespan. To date, BioAge has raised $127M from Andreessen Horowitz, Kaiser Foundation Hospitals, and others. Recently, BioAge in-licensed our first two Ph2-ready platform assets, BGE-117, a potent inhibitor of HIF PH which we are developing for muscle-related indications, and BGE-175, a PGD2 DP1 receptor inhibitor which we are developing for disorders of the aging immune system. For both programs we’ll be initiating Phase 2 efficacy trials by H1 2021. Our mission is to develop a pipeline of therapeutic assets that increase healthspan and lifespan. For additional information about BioAge, visit the company’s website at www.bioagelabs.com.

Contacts

BioAge | peng@bioagelabs.com

Industry:

BioAge Labs, Inc.

Release Summary
BioAge to Present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 2:00pm ET
Release Versions
English

Contacts

BioAge | peng@bioagelabs.com

Social Media Profiles
bioagelabs/linkedin
More News From BioAge Labs, Inc.

BioAge Appoints Former GSK CEO Jean-Pierre Garnier as Chair of Its Board of Directors

RICHMOND, Calif.--(BUSINESS WIRE)--BioAge Labs, Inc. (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced the appointment of Jean-Pierre Garnier, PhD, as Chair of the company’s Board of Directors. Garnier will succeed current Board Chair James Healy, MD, PhD, managing partner of Sofinnova Investments, who will remain on the Board. “We are excited to welcome JP to BioAge’s...

BioAge Announces First Patient Dosed in the STRIDES Phase 2 Clinical Trial Evaluating Azelaprag as a Novel Treatment for Obesity in Combination with Tirzepatide

RICHMOND, Calif.--(BUSINESS WIRE)--BioAge Labs, Inc., ("BioAge"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the first patient has been dosed in the STRIDES Phase 2 clinical trial evaluating BioAge’s lead product candidate azelaprag in combination with tirzepatide for the treatment of obesity in adults aged 55 and older. Azelaprag is an orally available small molecule a...

BioAge Labs Presents Preclinical Data for Apelin Receptor Agonist Azelaprag for Obesity Demonstrating Significant Improvements in Weight Loss and Body Composition When Combined with Incretin Drugs

RICHMOND, Calif.--(BUSINESS WIRE)--BioAge Labs, Inc. ("BioAge"), a clinical-stage biotechnology company developing therapeutic candidates for metabolic diseases, such as obesity, by targeting the biology of aging, today announced preclinical data for its lead product candidate azelaprag, an orally available small molecule agonist of the apelin receptor APJ, in combination with incretin agonists for the treatment of obesity. The data were presented in a talk by BioAge’s Chief Medical Officer and...
Back to Newsroom